We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Pilot Phase II Study of Capecitabine plus Cisplatin in the Treatment of Recurrent Carcinoma of the Uterine Cervix.
- Authors
Benjapibal, Mongkol; Thirapakawong, Chaiyod; Leelaphatanadit, Chairatana; Therasakvichya, Suwanit; Inthasorn, Perapong
- Abstract
Background: To assess the efficacy and tolerability of combination therapy with capecitabine and cisplatin in patients with recurrent carcinoma of the uterine cervix. Methods: Sixteen patients were treated with oral capecitabine (1,000 mg/m2 twice daily, days 1–14) and intravenous cisplatin (50 mg/m2 on day 1 every 3 weeks) for a maximum of six cycles. Results: Their median age was 50 years (31–74 years). Ten patients (63%) had recurrent disease outside the radiation field. The overall response rate was 50% (95% confidence interval 26–75%); 4 patients had complete response (25%). The overall response rate was 33% in patients with recurrent disease within the previous irradiated field and 60% in patients with tumor outside the irradiated field. The median time to progression was 9 months, with a median overall survival of 23 months. The majority of adverse events were mild and there were no grade 4 adverse events. Hematological toxicity was the most frequent adverse event with grade 3 neutropenia in 19% of patients. Grade 2 and 3 hand-foot syndrome occurred in 38 and 6% of the patients, respectively. There were no chemotherapy-related deaths. Conclusion: The combination of capecitabine plus cisplatin is a clinically active regimen with acceptable tolerability for patients with recurrent carcinoma of the uterine cervix. Copyright © 2007 S. Karger AG, Basel
- Subjects
CERVICAL cancer; COMBINATION drug therapy; CISPLATIN; CANCER relapse; ALKYLATING agents; ANTINEOPLASTIC agents
- Publication
Oncology, 2007, Vol 72, Issue 1/2, p33
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000111086